Our top pick for
24/5 trading
Amgen Inc is a drug manufacturers - general business with stocks listed in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$297.03 – an increase of 0.01% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Amgen
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Amgen. Find the share by name or ticker symbol: AMGN. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Amgen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$297.03, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Amgen, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Amgen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Have Amgen's shares ever split?
Amgen's shares were split on a 2:1 basis on 21 November 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Amgen shares at a glance
Information last updated 2025-07-12.
| 52-week range | US$249.0689 - US$336.0108 |
|---|---|
| 50-day moving average | US$283.5064 |
| 200-day moving average | US$292.9078 |
| Target price | US$314.27 |
| PE ratio | 27.3905 |
| Dividend yield | US$9.13 (3.41%) |
| Earnings per share (TTM) | US$10.78 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Amgen price performance over time
Historical closes compared with the last close of $297.03
| 1 week (2025-07-08) | 0.01% |
|---|---|
| 1 month (2025-06-13) | 0.61% |
| 3 months (2025-04-15) | 0.59% |
| 6 months (2025-01-15) | 10.44% |
| 1 year (2024-07-15) | -10.03% |
|---|---|
| 2 years (2023-07-14) | 30.60% |
| 3 years (2022-07-15) | 19.44% |
| 5 years (2020-07-15) | 17.26% |
Compare trading platforms to buy Amgen shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Amgen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Amgen stock?
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's P/E ratio
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Amgen shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Amgen's PEG ratio
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9825. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$15.7 billion (£12.4 billion).
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure stock profitability.
Amgen share price volatility
Over the last 12 months, Amgen's shares have ranged in value from as little as US$249.0689 up to US$336.0108. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.496. This would suggest that Amgen's shares are less volatile than average (for this exchange).
Amgen financials
| Revenue TTM | US$34.1 billion |
|---|---|
| Operating margin TTM | 28.73% |
| Gross profit TTM | US$23.6 billion |
| Return on assets TTM | 7.04% |
| Return on equity TTM | 105.67% |
| Profit margin | 17.39% |
| Book value | 11.544 |
| Market capitalisation | US$161.5 billion |
| EBITDA | US$15.7 billion |
TTM: trailing 12 months
Amgen share dividends
Dividend payout ratio: 44.61% of net profits
Recently Amgen has paid out, on average, around 44.61% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.41% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.41% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $9.13 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 5 June 2025. The latest dividend was paid out to all shareholders who bought their shares by 15 May 2025 (the "ex-dividend date").
Amgen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Amgen's total ESG risk score
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Amgen's environmental score
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Amgen's social score
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Amgen's governance score
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Amgen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Amgen Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 20.95 |
|---|---|
| Total ESG percentile | 23.7 |
| Environmental score | 1.53 |
| Environmental score percentile | 3 |
| Social score | 15.13 |
| Social score percentile | 3 |
| Governance score | 5.8 |
| Governance score percentile | 3 |
| Level of controversy | 2 |
Amgen overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen in the news
Frequently asked questions
More resources on Finder
Ask a question
More guides on Finder
-
How to invest in the Indian stock market from Australia
How to trade the NSE from Australia and get exposure to the top Indian stocks.
-
Best growth stocks under $10 in Australia (2025)
We used Finder's proprietary algorithm to find the 10 best stocks under $10 on the ASX.
-
Best stocks under $5 in Australia (2025)
We used Finder's proprietary algorithm to find Australian-listed companies that have strong fundamentals and have a share price under $5.
-
The best ASX penny stocks (updated weekly)
Best performers included Yandal Resources, Falcon Metals and Santa Fe Minerals.
-
Best performing stocks on the ASX (Updated weekly)
Top gainers included Iluka Resources, Johns Lyng Group and Metals X.
-
Tiger Brokers Australia review
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
-
The best ASX shares to buy in July 2025
Here are our algorithm-selected 20 Aussie stocks worth watching in 2025.
-
What are the best AI stocks on the ASX in 2025? Stocks and ETFs to watch
Here's what investors should know before adding AI stocks to their portfolios.
-
How to buy gold in Australia
If you’re thinking of investing in gold, our guide will explain how and where to buy gold in Australia as well as the pros and cons of investing in it.
-
The best share trading platforms in Australia
Follow these tips to find the best share trading platform for you.